Clarity Pharmaceuticals Announces that the US FDA Grants Rare Pediatric Disease Designation to Cu-67 SARTATE™ for the Treatment of Neuroblastoma
Sydney, Australia 3 June 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to 67Cu-SARTATE™, a therapy for the clinical management of neuroblastoma. The FDA defines a “rare pediatric disease” (RPD)…